POTI', Francesco
 Distribuzione geografica
Continente #
NA - Nord America 3.366
AS - Asia 2.866
EU - Europa 1.971
SA - Sud America 442
AF - Africa 186
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 1
Totale 8.839
Nazione #
US - Stati Uniti d'America 3.298
SG - Singapore 1.137
CN - Cina 785
IT - Italia 445
VN - Vietnam 396
BR - Brasile 345
IE - Irlanda 318
HK - Hong Kong 250
SE - Svezia 245
FI - Finlandia 210
DE - Germania 192
ZA - Sudafrica 143
UA - Ucraina 125
FR - Francia 98
NL - Olanda 94
TR - Turchia 82
RU - Federazione Russa 70
GB - Regno Unito 49
AR - Argentina 47
AT - Austria 44
CA - Canada 39
IN - India 31
ID - Indonesia 20
BD - Bangladesh 19
IQ - Iraq 19
JP - Giappone 19
KR - Corea 18
MX - Messico 17
BE - Belgio 16
CZ - Repubblica Ceca 13
PL - Polonia 13
CL - Cile 11
EC - Ecuador 10
PK - Pakistan 10
CI - Costa d'Avorio 9
SA - Arabia Saudita 9
JO - Giordania 8
PH - Filippine 8
UZ - Uzbekistan 8
CO - Colombia 7
ES - Italia 7
EU - Europa 7
MY - Malesia 7
TN - Tunisia 7
VE - Venezuela 7
PY - Paraguay 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
EG - Egitto 5
IR - Iran 5
MA - Marocco 5
RO - Romania 5
AL - Albania 4
BG - Bulgaria 4
LT - Lituania 4
TH - Thailandia 4
UY - Uruguay 4
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
HN - Honduras 2
HR - Croazia 2
PE - Perù 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
DO - Repubblica Dominicana 1
GF - Guiana Francese 1
GH - Ghana 1
GT - Guatemala 1
HU - Ungheria 1
JM - Giamaica 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NA - Namibia 1
NG - Nigeria 1
PA - Panama 1
PT - Portogallo 1
QA - Qatar 1
Totale 8.833
Città #
Singapore 584
Ashburn 370
Chandler 349
San Jose 328
Dublin 318
Santa Clara 274
Hong Kong 232
Beijing 203
Dallas 201
Ann Arbor 145
Jacksonville 140
Johannesburg 129
Ho Chi Minh City 122
Parma 111
Dearborn 108
Boardman 100
Hanoi 95
New York 88
Houston 87
Princeton 73
Izmir 68
Nanjing 65
Lauterbourg 62
Chicago 53
Wilmington 52
Hefei 47
Los Angeles 45
Shanghai 44
Vienna 36
Columbus 35
Helsinki 33
Moscow 32
San Mateo 31
Munich 30
São Paulo 29
Bremen 27
Toronto 27
Milan 24
Nanchang 24
Des Moines 23
Haiphong 22
Seattle 22
Hebei 20
Jinan 20
Rho 20
Shenyang 20
Buffalo 19
Council Bluffs 18
The Dalles 18
Brussels 16
Frankfurt am Main 16
Tokyo 16
Bologna 15
Jakarta 15
Jiaxing 15
Changsha 14
Da Nang 14
Fremont 14
Guangzhou 14
Tianjin 14
Belo Horizonte 13
Brooklyn 13
Orem 12
Seoul 12
Kunming 11
Modena 11
Brno 10
Fairfield 10
Rio de Janeiro 10
Turku 10
Abidjan 9
Denver 9
Warsaw 9
Washington 9
Zhengzhou 9
Biên Hòa 8
Manchester 8
Nuremberg 8
Stockholm 8
Amman 7
Chengdu 7
Grafing 7
Hangzhou 7
London 7
Phoenix 7
Redondo Beach 7
San Francisco 7
Tashkent 7
Baghdad 6
Hải Dương 6
Marseille 6
Riyadh 6
Rockville 6
Uberlândia 6
Amsterdam 5
Bergamo 5
Brasília 5
Düsseldorf 5
Faenza 5
Ottawa 5
Totale 5.504
Nome #
Treatments for COVID-19: emerging drugs against the coronavirus 249
PCSK9 ablation attenuates Aβ pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice 227
Abacavir, nevirapine, and ritonavir modulate intracellular calcium levels without affecting GHRH-mediated growth hormone secretion in somatotropic cells in vitro 215
Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability 214
Effects of the radiocontrast agent iodixanol on endothelial cell morphology and function. 186
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 182
A Short Term Administration of Cyclosporine A to Mice Inhibits the Reverse Cholesterol Transport from Macrophages 174
CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO BY REDUCING STEROL FECAL EXCRETION 163
PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) GENETIC DELETION ATTENUATES AMYLOID-. PATHOLOGY, NEUROINFLAMMATION AND IMPROVES COGNITIVE FUNCTIONS IN AN ALZHEIMER'S DISEASE MOUSE MODEL 159
Alcohol pattern consumption differently affects the efficiency of macrophage reverse cholesterol transport in vivo 154
Drug-drug interactions in polypharmacy patients: The impact of renal impairment 150
EFFETTI DEI MEZZI DI CONTRASTO E DELLA N-ACETILCISTEINA SU MORFOLOGIA E FUNZIONE DELLE CELLULE ENDOTELIALI UMANE 149
Cyclosporine A modulates the macrophage reverse cholesterol transport in vivo 145
Critical and emerging topics in dietary carbohydrates and health 143
LA CICLOSPORINA A INIBISCE IL TRASPORTO INVERSO DEL COLESTEROLO NEI TOPI 141
CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO BY REDUCING STEROL FECAL EXCRETION 141
LA CICLOSPORINA A RIDUCE IL TRASPORTO INVERSO DEL COLESTEROLO NEI TOPI ATTRAVERSO L’INIBIZIONE DELL’ESCREZIONE FECALE 141
Effetto della Ciclosporina A sul trasporto inverso del colesterolo in vivo 140
Macrophage, But Not Systemic, Apolipoprotein E Is Necessary for Macrophage Reverse Cholesterol Transport In Vivo 139
A SHORT TERM ADMINISTRATION OF CYCLOSPORINE A IMPAIRS THE REVERSE CHOLESTEROL TRANSPORT FROM MACROPHAGES IN VIVO 138
HDL and reverse cholesterol transport in humans and animals: Lessons from pre-clinical models and clinical studies 137
Polyphenol health effects on cardiovascular and neurodegenerative disorders: A review and meta-analysis 133
Effetto degli agonisti LXR sul trasporto inverso del colesterolo in vivo 133
EFFECTS OF RADIOLOGY CONTRAST MEDIA ON CULTURED HUMAN ENDOTHELIAL CELL MORPHOLOGY AND FUNCTION AND PROTECTIVE ACTION OF N-ACETYLCYSTEIN AND ROSUVASTATIN 132
'Spare' Luteinizing Hormone Receptors: Facts and Fiction 131
Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion 130
RUOLO DELLA SFINGOSINA 1-FOSFATO E DEL SUO RECETTORE S1P3 NEL TRASPORTO INVERSO DEL COLESTEROLO 126
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 120
TRASPORTO INVERSO DEL COLESTEROLO: FATTORI DETERMINANTI L’EFFICIENZA DEL PROCESSO 116
Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo 115
The LXR agonist T0901317 promotes the reverse cholesterol transport frommacrophages by increasing plasma efflux potential 115
Biglycan and atherosclerosis: Lessons from high cardiovascular risk conditions 112
Dual effect of statins on ABCA1-mediated lipid efflux from macrophages and hepatic cells 112
Aortic Gene Expression Profiles Show How ApoA-I Levels Modulate Inflammation, Lysosomal Activity, and Sphingolipid Metabolism in Murine Atherosclerosis 112
IN VIVO TREATMENT WITH CYCLOSPORINE A INCREASES EFFLUX POTENTIAL OF MOUSE PLASMA VIA ATP-BINDING CASSETTE TRANSPORTER ABCA1 111
Impact of dietary lipids on the reverse cholesterol transport: What we learned from animal studies 110
ROLE OF APOLIPOPROTEIN E IN THE REVERSE CHOLESTEROL TRANSPORT IN VIVO 109
Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis 109
Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) 108
Impact of apolipoprotein E (apoE) deficiency on reverse cholesterol transport in vivo 105
Sphingosine-1 phosphate induces cAMP/PKA-independent phosphorylation of the cAMP response element-binding protein (CREB) in granulosa cells 103
Effect of LXR agonists on reverse cholesterol transport in vivo 100
Elevating Endogenous Sphingosine-1-Phosphate (S1P) Levels Improves Endothelial Function and Ameliorates Atherosclerosis in Low Density Lipoprotein Receptor-Deficient (LDL-R-/-) Mice 96
Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of high-density lipoproteins and low-density lipoproteins in opposite ways 92
The liver-X-receptor agonist T0901317 stimulates in vivo reverse cholesterol transport in mice 92
Targeted invalidation of SR-B1 in macrophages reduces macrophage apoptosis and accelerates atherosclerosis 92
Apolipoprotein M and Sphingosine-1-Phosphate Receptor 1 Promote the Transendothelial Transport of High-Density Lipoprotein 92
Pharmacogenetics of GPCR variants: FSH receptor and infertility treatment 91
Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice 89
Effect of the LXR agonist T0901317 on reverse cholesterol transport in vivo 86
Meccanismo di attivazione dell’ATP-binding cassette A1 da parte del cAMP 86
EFFECTS OF RADIOLOGY CONTRAST MEDIA ON CULTURED HUMAN ENDOTHELIAL CELL MORPHOLOGY AND FUNCTION AND PROTECTIVE ACTION OF N-ACETYLCYSTEIN AND ROSUVASTATIN 86
COVID-19 … What are drugs and strategies now? 85
The in vivo stimulation of LXR promotes the reverse cholesterol transport in vivo by increasing the efflux potential of sera 85
La rosuvastatina promuove il trasporto inverso del colesterolo nei topi 84
Editorial: Pharmacology of endocrine related GPCRs 83
Il cAMP attiva l’ATP-Binding Cassette A1 (ABCA1) attraverso un duplice meccanismo 83
Inferring biallelism of two FSH receptor mutations associated with spontaneous ovarian hyperstimulation syndrome by evaluating FSH, LH and HCG cross-activity 82
Identification of sclerostin as a putative new myokine involved in the muscle-to-bone crosstalk 82
LH increases the response to FSH in granulosa-lutein cells from sub/poor-responder patients in vitro 81
The LXR agonist T0901317 increases the efflux potential of sera and promotes the reverse cholesterol transport in mice 81
In vivo stimulation of LXR increases the efflux potential of sera and promotes the reverse cholesterol transport 79
SKI-II - a sphingosine kinase 1 inhibitor - exacerbates atherosclerosisin low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet 79
Gnrh antagonists produce differential modulation of the signaling pathways mediated by gnrh receptors 79
Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP 77
Human LH and hCG stimulate differently the early signalling pathways but result in equal testosterone synthesis in mouse Leydig cells in vitro 74
Sphingolipids and atherosclerosis: focus on Sphingosine 1-Phosphate (S1P) 74
Glycosylation pattern and in vitro bioactivity of reference follitropin alfa and biosimilars 73
High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression 73
Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R-/-) mice 71
Sphingosine 1-Phosphate (S1P): a bridge between HDL, inflammation and atherosclerosis? 70
Seizures of illicit substances for personal use in two Italian provinces: Analysis of trends by type and purity from 2008 to 2017 70
KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-R-/-mice 69
Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R -/-) mice 66
Sphingosine 1-phosphate receptor 1 signaling in macrophages reduces atherosclerosis in LDL receptor–deficient mice 65
WISP-2 expression induced by Teriparatide treatment affects in vitro osteoblast differentiation and improves in vivo osteogenesis 61
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 61
Osteocytes specific GSK3 inhibition affects in vitro osteogenic differentiation 58
The “hitchhiker’s guide to the galaxy” of endothelial dysfunction markers in human fertility 58
Molecular basis of androgen action on human sexual desire 54
Treatments for COVID-19: Emerging drugs against the coronavirus-reply 54
Totale 8.942
Categoria #
all - tutte 31.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.746


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021126 0 0 0 0 0 0 0 0 0 12 85 29
2021/2022399 21 15 16 9 25 18 65 54 20 27 6 123
2022/20231.260 140 100 79 114 131 147 13 89 380 14 41 12
2023/2024557 23 42 13 21 26 140 31 54 19 34 45 109
2024/20251.732 46 88 115 126 185 210 49 63 231 152 134 333
2025/20263.376 356 396 443 273 578 147 397 162 407 217 0 0
Totale 8.942